160 related articles for article (PubMed ID: 33781877)
1. Repurposing of Guanabenz acetate by encapsulation into long-circulating nanopolymersomes for treatment of triple-negative breast cancer.
Haggag YA; Yasser M; Tambuwala MM; El Tokhy SS; Isreb M; Donia AA
Int J Pharm; 2021 May; 600():120532. PubMed ID: 33781877
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect and metabolic fingerprinting of triple-negative breast cancer cells following exposure to a novel pH-responsive, gambogic acid-loaded micelle.
Da M; Li S; Yang R; Jia Z; Ma Y; Qi F; Zhao J; Shen G; Chen D
Nanotechnology; 2023 Dec; 35(11):. PubMed ID: 38081078
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
5. A novel redox/pH dual-responsive and hyaluronic acid-decorated multifunctional magnetic complex micelle for targeted gambogic acid delivery for the treatment of triple negative breast cancer.
Sang MM; Liu FL; Wang Y; Luo RJ; Huan XX; Han LF; Zhang ZT; Feng F; Qu W; Liu W; Zheng F
Drug Deliv; 2018 Nov; 25(1):1846-1857. PubMed ID: 30334478
[TBL] [Abstract][Full Text] [Related]
6.
Yang R; Lu M; Ming L; Chen Y; Cheng K; Zhou J; Jiang S; Lin Z; Chen D
Int J Nanomedicine; 2020; 15():9061-9074. PubMed ID: 33239874
[TBL] [Abstract][Full Text] [Related]
7. Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles.
Chen R; Ni S; Chen W; Liu M; Feng J; Hu K
Int J Nanomedicine; 2021; 16():5265-5279. PubMed ID: 34376979
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of malignant phenotypes of breast cancer cells through eIF2α-mediated downregulation of Rac1 signaling.
Hamamura K; Minami K; Tanjung N; Wan Q; Koizumi M; Matsuura N; Na S; Yokota H
Int J Oncol; 2014 Jun; 44(6):1980-8. PubMed ID: 24691491
[TBL] [Abstract][Full Text] [Related]
11. Repurposing maduramicin as a novel anticancer and anti-metastasis agent for triple-negative breast cancer as enhanced by nanoemulsion.
Song X; Zhang Y; Zuo R; Zhang J; Lin M; Wang J; Hu S; Ji H; Peng L; Lv Y; Gao X; Jiang S; Guo D
Int J Pharm; 2022 Sep; 625():122091. PubMed ID: 35964826
[TBL] [Abstract][Full Text] [Related]
12. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-loaded (PEG)₃-PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study.
Ayen WY; Garkhal K; Kumar N
Mol Pharm; 2011 Apr; 8(2):466-78. PubMed ID: 21288047
[TBL] [Abstract][Full Text] [Related]
14. The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model.
Alibolandi M; Sadeghi F; Abnous K; Atyabi F; Ramezani M; Hadizadeh F
Eur J Pharm Biopharm; 2015 Aug; 94():521-31. PubMed ID: 26170161
[TBL] [Abstract][Full Text] [Related]
15. α
Zhong P; Gu X; Cheng R; Deng C; Meng F; Zhong Z
Int J Nanomedicine; 2017; 12():7913-7921. PubMed ID: 29138558
[TBL] [Abstract][Full Text] [Related]
16. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.
Agnello L; Tortorella S; d'Argenio A; Carbone C; Camorani S; Locatelli E; Auletta L; Sorrentino D; Fedele M; Zannetti A; Franchini MC; Cerchia L
J Exp Clin Cancer Res; 2021 Jul; 40(1):239. PubMed ID: 34294133
[TBL] [Abstract][Full Text] [Related]
17. Clathrin-mediated endocytic uptake of PUFA enriched self-nanoemulsifying lipidic systems (SNELS) of an anticancer drug against triple negative cancer and DMBA induced preclinical tumor model.
Khurana RK; Kumar R; Gaspar BL; Welsby G; Welsby P; Kesharwani P; Katare OP; Singh KK; Singh B
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():645-658. PubMed ID: 30033299
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers.
Kutty RV; Feng SS
Biomaterials; 2013 Dec; 34(38):10160-71. PubMed ID: 24090836
[TBL] [Abstract][Full Text] [Related]
19. Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer.
Doddapaneni R; Patel K; Owaid IH; Singh M
Drug Deliv; 2016 May; 23(4):1232-41. PubMed ID: 26701717
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
